Biotechnology sector performed well on both public and private markets. Large public biotech stocks continued to climb while smaller stocks remained leveled. Private financing deal flow increased substantially, albeit leaving early stage start-ups behind. Biotech sector experienced an overall increase in VC activity during 2Q 2013 and after much less inspiring first quarter. The comeback of VC funding was consistent with strong public markets as well as high, 13, number of completed Life Sciences IPO transactions.
7 Areas to Transform Your Financial Reporting Valuation
Creating shareholder value is the goal of most for-profit entities, where value is viewed in a strictly financial sense. In the world of startups and VCs, this means maximizing exit valuations. That exit valuation number is of fundamental importance. Exit valuations are built over time. Thus, tracking valuations is critical. Companies have many opportunities to track their valuations, from upgraded